The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | The value of treating smoldering Waldenström’s macroglobulinemia
In this video, Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the value of early interception in Waldenström’s macroglobulinemia (WM), and explains the importance of obtaining clinical trial data in this space and treating patients with smoldering WM before symptoms appear. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
